Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET)

NCT03029143 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT03029143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03029143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET)
Lead sponsor
Takeda
Phase
Phase 4
Overall status
Completed
Start date
March 29, 2017
Completion date
October 16, 2020
Enrollment
278 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

colitis, ulcerative